- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01788306
Project OOPEN: Opioid Overdose Prevention, Education and Intervention (OOPEN)
A Trial to Prevent Opioid Overdose: E.D. Based Intervention & Take-home Naloxone
This prospective, randomized emergency department trial will study the effectiveness of an intervention that combines opioid overdose prevention, education and intervention that includes take home naloxone with brief behavioral change counseling. The study will recruit both heroin users (n=500) and pharmaceutical opioid users at elevated risk for overdose (n=500). Outcomes of interest include subsequent opioid overdoses and overdose risk behaviors.
Primary Aims
The primary aims are to test whether those who receive the intervention compared to standard care have: 1) Lower rates of opioid non-fatal and fatal overdose; 2) Reduce drug use, inappropriate medication use, and other overdose risk behaviors.
Secondary Aims
The secondary aims are to test whether those who receive the intervention compared to standard care have: 3) More appropriate health care utilization (e.g. fewer emergency department visits and admissions to inpatient care); 4) Lower total health care costs; 5) Determine the prevalence of HIV risk behaviors among heroin and pharmaceutical opioid users at risk for overdose and whether the intervention impacts these behaviors.
Study Overview
Detailed Description
Fatal overdoses involving pharmaceutical opioids have increased dramatically over the past decade, surpassing those related to heroin, and are the leading cause of drug overdose in much of the U.S. In Seattle-King County, 75% of drug overdoses involved pharmaceutical opioids and/or heroin in 2009. Opioid overdoses, heroin and pharmaceutical, are preventable and reversible. Research indicates that drug users and their partners can be successfully trained to recognize and reverse overdoses with naloxone (an opioid antagonist medicine or "antidote").
Despite active heroin overdose prevention, education and intervention programs with naloxone (OOPEN) in 15 states with thousands of overdose reversals and no serious adverse events, rigorous studies of these programs on rates of subsequent heroin overdoses have not been conducted. No OOPEN programs or studies have yet been implemented for pharmaceutical opioid users at elevated risk for overdose. The Emergency Department (ED) setting holds great promise for identifying and recruiting those at elevated risk of both heroin and pharmaceutical opioid overdose: 1) the ED study site for this proposal provides most services to those needing care for acute opioid related medical problems in Seattle, and 2) patients' need for urgent medical attention may heighten their concern about potential harms from opioids.
Unique to this setting is the potential to identify high risk pharmaceutical opioid users, a population that is difficult to locate and engage. ED interventions using brief behavior change counseling (BBCC) have been shown to significantly improve health behaviors such as alcohol use and injury, to increase entry into drug treatment as well as to reduce costs. Evidence is promising, but limited, regarding the impact of BBCC on opioid related risk behaviors.
This prospective, randomized ED trial will study the effectiveness of an intervention that combines OOPEN with BBCC for both heroin users (n=500) and pharmaceutical opioid users at elevated risk for overdose (n=500). The primary outcome is subsequent opioid overdoses, ascertained by follow up interviews conducted at 3, 6 and 12 months as well as via administrative records for up to 24 months (i.e. medical records, ambulance responses, and death certificates).
Primary Aims
The primary aims are to test whether those who receive the intervention compared to standard care have: 1) Lower rates of opioid non-fatal and fatal overdose; 2) Reduce drug use, inappropriate medication use, and other overdose risk behaviors.
Secondary Aims
The secondary aims are to test whether those who receive the intervention compared to standard care have: 3) More appropriate health care utilization (e.g. fewer emergency department visits and admissions to inpatient care); 4) Lower total health care costs; 5) Determine the prevalence of HIV risk behaviors among heroin and pharmaceutical opioid users at risk for overdose and whether the intervention impacts these behaviors.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
Seattle, Washington, United States, 98134
- Evergreen Treatment Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Meets study definition of elevated risk of future opioid overdose
- Reason for visit is opioid overdose (regardless of frequency of use), or
- Use of pharmaceutical opioids not prescribed to the patient 2 or more times in the prior month, or
- Use of other opioids, alcohol, benzodiazepines or stimulants within two hours of using opioids 2 or more times in the prior month, or
- Average daily dose of prescribed opioids consumed is greater than10 mg morphine equivalent analgesic dose or higher for 15 or more days in the last 30.
- Enrolled in opioid substitution program (e.g. methadone or suboxone) and receiving doses.
- Use of heroin through any route of administration at least 2 times in the last 30 days (or if institutionalized recently, in the most recent month they were not institutionalized) with or without other risks being present.
- Use of pharmaceutical opioids at least 2 times in the last 30 days (or if institutionalized recently, in the most recent month they were not institutionalized) with other risks being present.
- Average daily dose of prescribed opioids consumed is 30 mg morphine equivalent analgesic dose or higher without other risks being present.(For adult medicine clinic patients only.)
Exclusion Criteria:
- Unwilling to allow further access to medical or drug treatment records.
- Inability to communicate in English.
- Current active suicidal ideation.
- Significant cognitive or psychiatric impairment (per judgment of clinical staff)
- Inability to provide adequate contact information to assist with follow-up.
- Under age 18 or over age 70 at time of recruitment.
- Not currently living in Washington State or planning to move from Washington State within the following year.
- Receiving treatment for sexual assault.
- Have non-expired take-home naloxone at home, on their person, or in their possessions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention (OOPEN+BBCC)
Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
|
Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
|
No Intervention: Control
Standard of care, referral to local available resources.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Fatal Opioid Overdose
Time Frame: One year
|
Rate of fatal opioid overdose
|
One year
|
Rate of Non-fatal Opioid Overdose
Time Frame: One year
|
Rate of non-fatal opioid overdose
|
One year
|
Elapsed Time Until Opioid Overdose
Time Frame: Up to1064 days
|
Elapsed time until opioid overdose
|
Up to1064 days
|
Change in Overdose Risk (Change in Opioid Use - Heroin)
Time Frame: 3 months
|
Determine whether changes in behavior occur that increase or decrease risk of future overdose.
Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Change in Overdose Risk (Change in Opioid Use - Prescription-Type Opioids)
Time Frame: 3 months
|
Determine whether changes in behavior occur that increase or decrease risk of future overdose.
Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Change in Overdose Risk (Using Alone When Taking Opioids)
Time Frame: 3 months
|
Determine whether changes in behavior occur that increase or decrease risk of future overdose.
Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.
(Data table includes means at 3 month follow-up.)
|
3 months
|
Change in Overdose Risk (Use of Sedatives When Taking Opioids)
Time Frame: 3 months
|
Determine whether changes in behavior occur that increase or decrease risk of future overdose.
Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.
(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Change in Overdose Risk (Use of Alcohol When Taking Opioids)
Time Frame: 3 months
|
Determine whether changes in behavior occur that increase or decrease risk of future overdose.
Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Care Utilization (ED and Inpatient Admissions)
Time Frame: One year (annual rate)
|
Appropriate health care utilization (e.g.
fewer emergency department visits and admissions to inpatient care)
|
One year (annual rate)
|
Change in HIV Risk Behaviors (Condom Use)
Time Frame: 3 months
|
Determine whether change occurs in the number of sexual risk behaviors (such as engaging in intercourse without a condom) and/or injection use behaviors (such as sharing syringes) that may increase the risk of contracting HIV.(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Change in HIV Risk Behaviors (Shared Syringes)
Time Frame: 3 months
|
Determine whether change occurs in the number of sexual risk behaviors (such as engaging in intercourse without a condom) and/or injection use behaviors (such as sharing syringes) that may increase the risk of contracting HIV.
(Data table includes proportions at 3 month follow-up.)
|
3 months
|
Change in Overdose Risk Behaviors and Perceptions (Take Home Naloxone)
Time Frame: 3 Months
|
Change in overdose response including naloxone availability and change in overdose risk perceptions.
(Data table includes proportions at 3 month follow-up.)
|
3 Months
|
Change in Overdose Risk Behaviors and Perceptions (Likelihood of Overdose)
Time Frame: 3 Months
|
Change in overdose response including naloxone availability and change in overdose risk perceptions.
(Data table includes proportions at 3 month follow-up.)
|
3 Months
|
Change in Overdose Risk Behaviors and Perceptions (Concerned About Overdose)
Time Frame: 3 Months
|
Change in overdose response including naloxone availability and change in overdose risk perceptions.
(Data table includes proportions at 3 month follow-up.)
|
3 Months
|
Subgroup Analyses - Change in HIV Risk Behaviors (Condom Use)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Subgroup Analyses - Change in HIV Risk Behaviors (Shared Syringes)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Sub-group Analyses - Change in Overdose Risk (Change in Opioid Use - Heroin)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Sub-group Analyses - Change in Overdose Risk (Change in Opioid Use - Prescription Type Opioids)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Sub-group Analyses - Change in Overdose Risk (Using Alone When Taking Opioids)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes means at 3 month follow-up.)
|
3 months
|
Subgroup Analyses- Change in Overdose Risk (Use of Sedatives When Taking Opioids)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Subgroup Analyses- Change in Overdose Risk (Use of Alcohol When Taking Opioids)
Time Frame: 3 months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 months
|
Sub-group Analyses - Change in Overdose Risk Behaviors and Perceptions (Take Home Naloxone)
Time Frame: 3 Months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 Months
|
Sub-group Analyses- Change in Overdose Risk Behaviors and Perceptions (Likelihood of Overdose)
Time Frame: 3 Months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 Months
|
Sub-group Analyses- Change in Overdose Risk Behaviors and Perceptions (Concerned About Overdose)
Time Frame: 3 Months
|
Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data
table includes proportions at 3 month follow-up.)
|
3 Months
|
Health Care Costs
Time Frame: Two years
|
Total health care costs
|
Two years
|
Health Care Utilization
Time Frame: Two years
|
Rate and elapsed time until initiation of buprenorphine or methadone maintenance.
(for those not on treatment medications)
|
Two years
|
Health Care Utilization
Time Frame: Two years
|
Retention time on buprenorphine or methadone (for those on medications at baseline)
|
Two years
|
Opioid Overdose - Crossover Analysis
Time Frame: Two years
|
Crossover analysis- Comparison group participants who obtain naloxone during the follow up period will be analyzed with those in the intervention arm and compared with those who did not obtain naloxone in the comparison arm to examine differences in overdose rates and elapsed time to overdose.
|
Two years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 43874
- 1R01DA030351 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Overdose
-
Isfahan University of Medical SciencesCompletedMorphinan Opioid OverdoseIran, Islamic Republic of
-
Edward HospitalCompletedOpioid Use Disorder | Opioid DependenceUnited States
-
BC Centre on Substance UseIndivior Inc.RecruitingOpioid Overdose | Opioid-Use DisorderCanada
-
Unity Health TorontoUniversity of Toronto; Toronto Public Health; Ontario College of Art and Design...WithdrawnOpioid-Related Disorders | Opioid Use | Education | Opioid Withdrawal | Opioid Overdose | ResusitationCanada
-
University of CincinnatiCompletedOpioid Dependence | Substance Abuse | Overdose | Drug Overdose | Drug Abuse | Drug Addiction | Opioid-related Disorders | Opioid Use, UnspecifiedUnited States
-
University of PennsylvaniaCompletedSubstance Use Disorders | Opioid-use Disorder | Opioid OverdoseUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Indivior Inc.Completed
-
RTI InternationalNational Institute on Drug Abuse (NIDA)Unknown
-
VA Office of Research and DevelopmentCompletedPain | Drug Overdose | Opioid Use DisordersUnited States
-
Cessation Therapeutics, Inc.Dr. Vince Clinical ResearchRecruitingOpioid Use Disorder | Opioid OverdoseUnited States
Clinical Trials on OOPEN+BBCC
-
Kamuzu University of Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)UnknownHypertension | Diabetes | Life StyleMalawi